RG1068 (Synthetic Human Secretin)
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obsessive Compulsive Disorder (OCD)
Conditions
Obsessive Compulsive Disorder (OCD)
Trial Timeline
Feb 1, 2005 → Apr 1, 2006
NCT ID
NCT00216294About RG1068 (Synthetic Human Secretin)
RG1068 (Synthetic Human Secretin) is a phase 2 stage product being developed by Repligen for Obsessive Compulsive Disorder (OCD). The current trial status is completed. This product is registered under clinical trial identifier NCT00216294. Target conditions include Obsessive Compulsive Disorder (OCD).
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00660335 | Phase 3 | Completed |
| NCT00216294 | Phase 2 | Completed |
| NCT00036231 | Phase 3 | Terminated |
| NCT00036244 | Phase 3 | Completed |
Competing Products
17 competing products in Obsessive Compulsive Disorder (OCD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine | Eli Lilly | Approved | 85 |
| Fluvoxamine maleate + Placebo | AbbVie | Phase 3 | 77 |
| quetiapine fumarate + SSRI/Clomipramine | AstraZeneca | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 2 | 52 |
| Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo) | Novartis | Approved | 85 |
| Bitopertin + Placebo + SSRI | Roche | Phase 2 | 52 |
| sertraline | Pfizer | Pre-clinical | 22 |
| pregabalin + Placebo | Pfizer | Approved | 84 |
| Sertraline + Levetiracetam + Placebo | UCB | Phase 2/3 | 62 |
| Escitalopram | Lundbeck | Approved | 82 |
| Escitalopram + Placebo oral tablet | Lundbeck | Approved | 82 |
| Valbenazine + Placebo | Neurocrine Biosciences | Phase 2 | 49 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 3 | 72 |
| Troriluzole + Placebo | Biohaven | Phase 2/3 | 60 |
| Troriluzole (BHV-4157) | Biohaven | Phase 3 | 72 |
| Nitrous Oxide + Nitrogen | Brain Biotech | Phase 2 | 44 |